Sign In
Buy CODX
$1.44
-0.120 (-7.69%)
At Close: Jul 31, 2026
Lease execution highlights transition from approval to development and advances localized manufacturing strategy in the Kingdom of Saudi Arabia in accordance with Vision 2030 SALT LAKE CITY, May 8, 20
Co-Diagnostics Announces First Quarter 2026 Earnings Release Date and Webcast
09:00am, Thursday, 30'th Apr 2026
SALT LAKE CITY, April 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C.
09:00am, Thursday, 16'th Apr 2026
MTB test on Co-Dx PCR platform* to be presented at roundtable with Stop TB Partnership, U.S. Department of State, and global stakeholders SALT LAKE CITY, April 16, 2026 /PRNewswire/ -- Co-Diagnostics,
Co-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, Germany
09:00am, Tuesday, 14'th Apr 2026
Company to engage with global customers and distributors while expanding international commercial relationships SALT LAKE CITY, April 14, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (t
Co-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah
09:00am, Thursday, 09'th Apr 2026
Trade mission itinerary of business, government, and industry briefings across Switzerland and Germany to include site visits to Roche Diagnostics, UBS, Zurich Innovation Park and more SALT LAKE CITY,
Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript
02:42am, Wednesday, 01'st Apr 2026
Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript
Co-Diagnostics Reports Full Year 2025 Financial Results
04:01pm, Tuesday, 31'st Mar 2026
Advancing Global Commercialization Strategy Through CoSara and CoMira Joint Ventures Progressing Clinical Pipeline and Regulatory Pathways for PCR Platform Strengthening Technology Leadership with AI
The near-term commencement of clinical studies is expected to align with recent WHO tuberculosis recommendations for near-point-of-care molecular testing and utilizing tongue swab samples New recommen
EXCLUSIVE: Co-Diagnostics Ships Diagnostic Tests To India Ahead Of TB Study Launch
07:46am, Wednesday, 25'th Mar 2026
These materials are necessary to begin clinical performance studies of the TB test on the PCR platform, as the company completes final steps toward initiating those studies in the near term.
Co-Diagnostics Signs Agreement to Significantly Expand Commercial and Distribution Territory Across South Asia
08:00am, Friday, 20'th Mar 2026
Expansion into Bangladesh, Pakistan, Nepal, and Sri Lanka increases TAM in region to $13 billion and supports commercialization strategy for the PCR Pro ® and SARAGENE ® product line SALT LAKE CITY,
EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity
07:56am, Friday, 20'th Mar 2026
CoSara is the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited.
Co-Diagnostics Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Webcast
09:00am, Tuesday, 17'th Mar 2026
SALT LAKE CITY, March 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics to Present at Medical Korea 2026
09:00am, Monday, 16'th Mar 2026
Co-Dx to join WTC Utah and other Utah legislative and industry delegates March 19-22 in Seoul, South Korea SALT LAKE CITY, March 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" o
Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies
09:00am, Thursday, 12'th Mar 2026
SALT LAKE CITY, March 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of m
Co-Diagnostics Regains Compliance with Nasdaq Listing Requirements
09:00am, Tuesday, 10'th Mar 2026
SALT LAKE CITY, March 10, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of
